Market closedADR

BeiGene/$BGNE

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About BeiGene

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Ticker

$BGNE
Trading on

Industry

Biotechnology

Headquarters

Camana Bay, Cayman Islands

Employees

10,000

BeiGene Metrics

BasicAdvanced
$22B
Market cap
-
P/E ratio
-$5.01
EPS
0.63
Beta
-
Dividend rate
$22B
0.63
$243.06
$126.97
354K
1.98
1.641
30.804
30.804
-242.90%
-9.69%
-14.62%
6.915
6.46
6.57
-15.789
71.01%
-69.89%
48.42%
-30.06%

What the Analysts think about BeiGene

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for BeiGene stock.

BeiGene Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BeiGene Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BGNE

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BeiGene stock?

BeiGene (BGNE) has a market cap of $22B as of November 13, 2024.

What is the P/E ratio for BeiGene stock?

The price to earnings (P/E) ratio for BeiGene (BGNE) stock is 0 as of November 13, 2024.

Does BeiGene stock pay dividends?

No, BeiGene (BGNE) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next BeiGene dividend payment date?

BeiGene (BGNE) stock does not pay dividends to its shareholders.

What is the beta indicator for BeiGene?

BeiGene (BGNE) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.